Table 1.
FDA Approved SGLT2 Inhibitors
| Drug Name | Dosagea (mg) | Reduction In HbA1cb | SGLT2 IC50c (nmol/L) | Considerations For Patients | Cardiovascular Outcomes | Future Potential Uses In Non-DM |
|---|---|---|---|---|---|---|
| Canagliflozin (Invokana) | 100, 300 | −0.77, −1.03 | 2.7 | Strongest effect on reducing BP; Increased risk of lower limb amputations | CANVAS program30 Reduced risk of i) death from cardiovascular events, ii) nonfatal myocardial infarction, and iii) nonfatal stroke |
NAFLD SIADH Heart failure Weight loss High cholesterol Alzheimer’s disease Coronary artery disease Ischemic heart disease |
| Empagliflozin (Jardiance) | 10, 25 | −0.66, −0.78 | 3.1 | Use in patients with previous stroke or MI | EMPA-REG OUTCOME26 Reduced HHF and death from cardiovascular causes |
|
| Dapagliflozin (Farxiga) | 5, 10 | −0.82, −0.89 | 1.2 | Positive effects on LDL-C and HDL-C | DECLARE-TIMI 5829 Reduced HHF and CVD |
|
| Ertugliflozin (Steglatro) | 5, 15 | −0.99, −1.16 | 0.9 | Stricter eGFR restriction(<60 mL/min/1.73m2) | VERTIS-CV Estimated Completion Date: December 2019 |
Notes: aAll dosages are once per day (qd). bPercentage reduction from baseline 24–26 weeks. cTaken from reference.128
Abbreviations: FDA, Food and Drug Administration; SGLT2, Sodium-Glucose Cotransporter-2; HbA1c, Hemoglobin A1c; BP, blood pressure; MI, myocardial infarction; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.